I consent to receiving electronic communication to the above e-mail address from MEDAPP S.A. with registered office in Kraków, 30-150 Kraków, ul. Armii Krajowej 25, NIP (tax ID): 7010264750, REGON (company register ID): 142641690, with KRS (National Court Register) number 00000365157, whose registration documents are held by the District Court for Kraków-Śródmieście in Kraków, 11thEconomic Division of the National Court Register, in order to receive commercial information concerning MEDAPP S.A. products and services
I consent to receiving commercial information concerning MEDAPP S.A. products and services from MEDAPP S.A. with registered office in Kraków, 30-150 Kraków, ul. Armii Krajowej 25, NIP (tax ID): 7010264750, REGON (company register ID): 142641690, with KRS (National Court Register) number 00000365157, whose registration documents are held by the District Court for Kraków-Śródmieście in Kraków, 11th Economic Division of the National Court Register, to the telephone number provided above (text messages, calls).
I certify that I have read and understand the Privacy policy. You may withdraw your consent at any time by contacting us at iodo@medapp.pl. Your telecommunications terminal equipment (e.g. telephone/computer) and automated calling systems within the meaning of the Telecommunications Law (i.e. Journal of Laws 2021, item 576 as amended) will be used for sending commercial information.
Wir laden Sie ein, die wichtigsten Ereignisse des Jahres 2021 in unserem Unternehmen zusammenzufassen.
Zobacz podobne wpisy:
12 września 2022
We are looking for companies and individuals interested in distributing MedApp’s medical technology.
CarnaLife Holo is a breakthrough technology for 3D visualization of imaged medical data which supports the planning and performance of medical procedures. With the help of Microsoft’s HoloLens 2, the physician can see in real space a three-dimensional hologram reflecting the structure of the imaged anatomical area.
MedApp nach Q2 2022: Ein weiteres Quartal der geografischen und produktbezogenen Expansion
MedApp, ein börsennotiertes Unternehmen der innovativen Medizintechnikbranche, verzeichnete im zweiten Quartal 2022 einen Nettoumsatz von 1,588 Mio. PLN, einen EBITDA Ergebnis von 878 Tsd. PLN und einen Nettogewinn von 405 Tsd. PLN, trotz der zunehmenden Unsicherheit im Geschäftsumfeld und der Herausforderungen, denen sich medizinische Einrichtungen gegenübersehen.
MedApp after Q2 2022: Another Quarter of Geographic and Product Expansion
MedApp, a publicly listed company in the innovative medical technology industry, recorded net sales of PLN 1,588 million, PLN 878 thousand EBITDA earnings and PLN 405 thousand net profit in the second quarter of 2022, despite the increasing uncertainty in the business environment and the challenges facing medical facilities.
